Company Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:08:40 2024-03-28 am EDT 5-day change 1st Jan Change
5.55 USD -4.97% Intraday chart for Syros Pharmaceuticals, Inc. -12.30% -28.63%

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RAR?), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company's product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.

Number of employees: 117

Sales per Business

USD in Million2021Weight2022Weight Delta
Gene Control Medicines
100.0 %
23 100.0 % 15 100.0 % -36.65%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
23 100.0 % 15 100.0 % -36.65%

Managers

Managers TitleAgeSince
Chief Executive Officer 54 21-09-26
Director of Finance/CFO 56 21-10-11
Chief Tech/Sci/R&D Officer 61 15-12-06
Chief Administrative Officer 56 16-08-31
Investor Relations Contact - 22-09-30
Human Resources Officer - 11-12-31
Corporate Officer/Principal 51 -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 56 17-06-11
Director/Board Member 71 22-09-15
Director/Board Member 70 15-10-18
Director/Board Member 61 21-09-08
Chairman 73 17-01-29
Founder 70 11-11-08
Director/Board Member 66 20-09-07
Director/Board Member 53 22-09-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,660,038 25,404,156 ( 99.00 %) 0 99.00 %

Shareholders

NameEquities%Valuation
Bain Capital Life Sciences LP
10.57 %
2,749,808 10.57 % 20 M $
Artal Group SA
9.632 %
2,505,013 9.632 % 18 M $
Adage Capital Partners GP LLC
7.967 %
2,071,914 7.967 % 15 M $
Samsara Biocapital LLC
6.869 %
1,786,427 6.869 % 13 M $
Avidity Partners Management LP
6.435 %
1,673,538 6.435 % 12 M $
Blue Owl Healthcare Opportunities Advisors LLC
5.742 %
1,493,252 5.742 % 11 M $
Point72 Asset Management LP
5.659 %
1,471,771 5.659 % 11 M $
CHI Advisors LLC
4.996 %
1,299,359 4.996 % 9 M $
Flagship Pioneering
4.975 %
1,293,848 4.975 % 9 M $
Deep Track Capital LP
3.186 %
828,485 3.186 % 6 M $

Company contact information

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive 4th floor

02140-2325, Cambridge

+617 744 1340

http://www.syros.com
address Syros Pharmaceuticals, Inc.(SYRS)